A detailed history of Stephens Consulting, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Stephens Consulting, LLC holds 55 shares of VRTX stock, worth $28,420. This represents 0.01% of its overall portfolio holdings.

Number of Shares
55
Previous 67 17.91%
Holding current value
$28,420
Previous $31.4 Million 18.55%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$460.0 - $505.78 $5,520 - $6,069
-12 Reduced 17.91%
55 $25.6 Million
Q2 2024

Jul 29, 2024

BUY
$392.81 - $485.53 $26,318 - $32,530
67 New
67 $31.4 Million
Q4 2022

Jan 19, 2023

SELL
$285.76 - $321.48 $37,720 - $42,435
-132 Closed
0 $0
Q1 2022

Jan 19, 2023

SELL
$221.42 - $260.97 $35,648 - $42,016
-161 Reduced 54.95%
132 $34.4 Million
Q4 2021

Jan 19, 2023

BUY
$177.01 - $223.45 $51,863 - $65,470
293 New
293 $64.3 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Stephens Consulting, LLC Portfolio

Follow Stephens Consulting, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stephens Consulting, LLC with notifications on news.